pramlintide · Symlin

Peptide

Approvedregulatory verdict

Evidence outlook

Approved: Type 2 Diabetes, Type 1 Diabetes

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

US marketing discontinued: Drugs@FDA lists every US product of this approval as discontinued.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (6)
Type 1 Diabetes
NCT00206297 · Baylor College of Medicine
2003-10 – 2006-02 · Type 1 Diabetes
What this study did
NCT00206258 · Baylor College of Medicine
2002-07 – 2005-08 · Type 1 Diabetes
What this study did
NCT00107107 · AstraZeneca
2002-11 – 2005-06 · Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT01137695 · Cheryl Rosenfeld, DO
2010-05 – 2012-04 · Type 2 Diabetes Mellitus
What this study did
Other / comorbidity
NCT00042458 · AstraZeneca
2002-04 – 2003-03 · Diabetes Mellitus, Type 1
What this study did
Phase 2/3 (2)
Type 1 Diabetes
NCT06046417 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2023-11-30 – 2025-06 · type1diabetes, Diabetes Mellitus, Type 1
What this study did
Other / comorbidity
NCT06619015 · Esbjerg Hospital - University Hospital of Southern Denmark
2025-04-01 – 2025-04-01 · Obesity, Appetite Regulation, PreDiabetes
What this study did
Phase 2 (15)
Type 1 Diabetes
NCT02814123 · McGill University
2017-01-13 – 2018-07-08 · Diabetes Mellitus, Type 1
What this study did
NCT00313183 · AstraZeneca
2006-04 – 2007-08 · Type 1 Diabetes Mellitus
What this study did
Type 2 Diabetes
NCT00042601 · AstraZeneca
2002-07 – 2003-10 · Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
What this study did
NCT00042471 · AstraZeneca
2002-06 – 2002-12 · Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
What this study did
NCT00044707 · AstraZeneca
2002-08 – 2002-09 · Diabetes Mellitus, Non-Insulin-Dependent
What this study did
Other / comorbidity
NCT03800875 · McGill University
2019-02-08 – 2020-09-19 · Diabetes Mellitus, Type 1
What this study did
NCT04074317 · Xeris Pharmaceuticals
2019-08-22 – 2020-04-02 · Diabetes Mellitus, Type 1, Insulin-dependent Diabetes Mellitus
What this study did
NCT01235741 · AstraZeneca
2011-01 – 2011-09 · Obesity
What this study did
NCT00392925 · AstraZeneca
2006-10 – 2007-09 · Overweight, Obesity
What this study did
NCT00189514 · AstraZeneca
2005-09 – 2007-06 · Obesity
What this study did
NCT00112021 · AstraZeneca
2005-05 – 2005-11 · Obesity
What this study did
NCT00444561 · AstraZeneca
2004-08 – 2005-05 · Overweight, Obesity
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT01165944 · University of Colorado, Denver
2009-08 – 2011-08 · Diabetes Mellitus
What this study did
Phase 1 (5)
Type 1 Diabetes
NCT02500979 · AstraZeneca
2015-08-17 – 2016-08-05 · Type 1 Diabetes Mellitus
What this study did
NCT01708044 · AstraZeneca
2012-11 – 2013-09 · Type 1 Diabetes
What this study did
NCT01269008 · Albert Einstein College of Medicine
2010-12 – 2013-01 · Type 1 Diabetes
What this study did
Other / comorbidity
NCT03560960 · Boston University
2020-02-04 – 2026-11 · Alzheimer Disease, Mild Cognitive Impairment
What this study did
NCT04252612 · H. Lee Moffitt Cancer Center and Research Institute
2020-01-30 – 2023-06-26 · Cutaneous Squamous Cell Carcinoma
What this study did
Phase 4 (10)
Type 1 Diabetes
NCT01269047 · Albert Einstein College of Medicine
2009-08 – 2016-12 · Type 1 Diabetes
What this study did
NCT00442767 · Montefiore Medical Center
2007-02 – 2009-02 · Type 1 Diabetes Mellitus
What this study did
NCT00505882 · University of Texas Southwestern Medical Center
2007-07 – 2008-12 · Type 1 Diabetes
What this study did
NCT00502138 · University Diabetes & Endocrine Consultants
2007-07 – 2008-01 · IDDM
What this study did
NCT00291772 · Baylor College of Medicine
2006-01 – 2007-11 · Type 1 Diabetes
What this study did
Type 2 Diabetes
NCT00950677 · Baylor College of Medicine
2009-07 – 2011-05 · Type 2 Diabetes
What this study did
NCT00467649 · AstraZeneca
2007-05 – 2008-04 · Type 2 Diabetes Mellitus
What this study did
NCT00240253 · AstraZeneca
2005-10 – 2006-06 · Type 2 Diabetes Mellitus
What this study did
Other / comorbidity
NCT01841359 · Joslin Diabetes Center
2010-02-02 – 2022-02-08 · Hypoglycemia, Evidence of Previous Gastric Surgery
What this study did
NCT00690235 · University of Texas Southwestern Medical Center
2007-11 – 2011-08 · Schizophrenia, Schizoaffective Disorder, Diabetes, Weight Gain
What this study did
Early phase / not applicable (18)
Type 1 Diabetes
NCT07914621 · Oregon Health and Science University
2026-11-02 – 2027-01-31 · Type 1 Diabetes
What this study did
NCT06422325 · Oregon Health and Science University
2024-07-12 – 2025-01-28 · Type 1 Diabetes
What this study did
NCT06186063 · Filip Krag Knop
2024-02-12 – 2024-08-01 · Bone Diseases, Metabolic, Type 1 Diabetes
What this study did
NCT04243629 · McGill University
2021-11-12 – 2024-04 · Diabetes Mellitus, Type 1, Type 1 Diabetes, Postprandial Hyperglycemia
What this study did
NCT05199714 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2022-02-21 – 2023-03-25 · Type 1 Diabetes
What this study did
NCT03993366 · McGill University
2019-03-01 – 2019-08-06 · Type 1 Diabetes Mellitus
What this study did
NCT03547427 · University of Virginia
2018-05-20 – 2019-03-11 · Type 1 Diabetes Mellitus
What this study did
NCT01839370 · University of Virginia
2013-07 – 2013-11 · Diabetes Mellitus, Type 1
What this study did
NCT01434862 · University of Virginia
2011-02 – 2012-02 · Type 1 Diabetes Mellitus
What this study did
NCT00842075 · University of Colorado, Denver
2006-12 – 2009-12 · Type 1 Diabetes
What this study did
NCT00460304 · Diabetes Care Center
2007-09 – 2008-11 · Type 1 Diabetes
What this study did
NCT00489645 · Ludwig-Maximilians - University of Munich
2005-01 – 2007-04 · Type 1 Diabetes
What this study did
Type 2 Diabetes
NCT00790699 · Texas Diabetes & Endocrinology, P.A.
2009-08 – 2011-11 · Type 1 Diabetes, Type 2 Diabetes
What this study did
NCT00732147 · University of Maryland, Baltimore
2009-04 – 2011-04 · Type 2 Diabetes
What this study did
Other / comorbidity
NCT07506369 · University Hospital, Gentofte, Copenhagen
2026-04 – 2028-10 · Obesity & Overweight
What this study did
NCT07679516 · University of Copenhagen
2026-07-19 – 2028-05 · Healthy Adult Participants, Bone Physiology, Bone Blood Flow Regulation, Peptide Hormones
What this study did
NCT00691158 · Oregon Health and Science University
2006-01 – 2024-07 · Obesity
What this study did
NCT03598075 · Danish Headache Center
2018-07-01 – 2019-12-31 · Migraine Without Aura
What this study did
Used as active comparator (3)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 1 (2)
Type 1 Diabetes
NCT03916640 · Adocia
2019-01-04 – 2019-03-01 · Type 1 Diabetes Mellitus
What this study did
Early phase / not applicable (1)
Type 1 Diabetes
NCT04163874 · McGill University
2020-02-14 – 2022-01-30 · Type 1 Diabetes, Type 1 Diabetes Mellitus, Hyperglycemia, Postprandial
What this study did

Competitive landscape

7 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Type 1 Diabetes: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Pramlintide (Symlin): this drugApprovedPeptideAmylin receptornot yet gradedNo reviewed efficacy summary in this indication
AfrezzaApprovedPeptideInsulinPartial signal
NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed
NCT01445951: Change in HbA1c from baseline to week 24 (LS mean): Technosphere Insulin (Gen2 inhaler) plus basal insulin -0.21% vs insulin aspart plus basal insulin -0.40%; difference 0.19% (95% CI 0.02 to 0.36), inside the pre-specified non-inferiority margin of 0.4% (CT.gov posted analysis).
Insulin Aspart (NovoLog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (Fiasp)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Degludec (Tresiba)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Detemir (Levemir)
ApprovedUS marketing discontinued
PeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Lantus)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Basaglar)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Toujeo)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glulisine (Apidra)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin HumanApproved—Insulinnot yet gradedNo reviewed efficacy summary in this indication
Insulin Lispro (Humalog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Lispro (Lyumjev)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin NPH (Humulin N)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
CadisegliatinPhase 3Small moleculeGlucokinasenot yet gradedNo reviewed efficacy summary in this indication
Eloralintide
Phase 3(overall)
PeptideAmylin receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Lenbelintide
Phase 3(overall)
PeptideAmylin receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Petrelintide
Phase 3(overall)
PeptideAmylin receptor, Amylin/calcitonin receptor (dual)
Partial signal(overall)
No reviewed efficacy summary in this indication
Sotagliflozin (Inpefa)Phase 3Small moleculeSGLT1/2 (dual)not yet gradedNo reviewed efficacy summary in this indication
ZimislecelPhase 3Cell therapyPancreatic islet cells (VX-880 is a stem cell-derived therapy, not a small molecule drug), Pancreatic islet cell replacementnot yet gradedNo reviewed efficacy summary in this indication
ABBV-295
Phase 2(overall)
PeptideAmylin receptor
Weak signal(overall)
No reviewed efficacy summary in this indication
IcovamenibPhase 2Small moleculeMeninnot yet gradedNo reviewed efficacy summary in this indication
MET-233i
Phase 1/2(overall)
PeptideAmylin receptor
Weak signal(overall)
No reviewed efficacy summary in this indication

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Symlin (pramlintide) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
November 2026 (1)
Phase 1Alzheimer Disease, Mild Cognitive ImpairmentActive not recruiting
Est. primary completion 2026-11 · NCT03560960 · CT.gov ↗
What to watch
2027 (1)
January 2027 (1)
Early phase / not applicableType 1 DiabetesNot yet recruiting
Est. primary completion 2027-01-31 · NCT07914621 · CT.gov ↗
What to watch
2028 (1)
May 2028 (1)
Early phase / not applicableHealthy Adult Participants, Bone Physiology, Bone Blood Flow Regulation, Peptide HormonesNot yet recruiting
Est. primary completion 2028-05 · NCT07679516 · CT.gov ↗
What to watch

See the full readout calendar ↗